Amgen’s chief executive and chairman Kevin Sharer to retire
pharmafile | December 16, 2011 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Amgen
Kevin Sharer, Amgen’s chairman and chief executive, has announced his retirement next year, leading the way for Robert Bradway to become the US firm’s new chief executive on 23 May, 2012.
Sharer, 63, joined Amgen in 1992 and served as president until 2000 when he was named chairman and chief executive.
It is the intention of the board of directors to elect Robert Bradway chairman of the board when Sharer retires from that position at the end of 2012.
Bradway, 48, currently president and chief operating officer, will become chief executive in May next year.
Bradway joined Amgen in 2006 as a vice president in operations and was appointed CFO in 2007, before bring named president and chief operating officer in 2010.
Prior to joining Amgen, Bradway worked for 19 years at Morgan Stanley.
Changes in R&D
Roger Perlmutter, the executive vice president of R&D, is also planning to retire next year, with Sean Harper to assume the role on 13 February 2012.
Perlmutter will then work with Amgen as a consultant to aid in the transition until February, 2013.
He joined Amgen in 2000, and during his tenure Amgen has gained approval for a number of new drugs.
Sean Harper, 49, will assume his new role on February 13 next year and will be responsible for Amgen’s global research and development functions.
He joined Amgen in 2002, and currently works as the firm’s senior vice president, global development and he serves as chief medical officer.
Related Content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer
Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) …

Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial
AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …






